3,4-二溴-5-苯基-2(5H)-呋喃酮 | 72857-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢呋喃
• 中文名称: 3,4-二溴-5-苯基-2(5H)-呋喃酮
• 英文名称: α,β-dibromo-γ-phenylcrotonolactone
• 英文别名: 3,4-dibromo-5-phenylfuran-2(5H)-one；2,3-dibromo-4-phenylcrotonolactone；3,4-dibromo-5-phenyl-5H-furan-2-one；3,4-Dibrom-5-phenyl-5H-furan-2-on；4-Phenyl-2,3-dibrom-Δ^2.3-crotonlacton；3,4-dibromo-5-phenyl-2(5H)-furanone；3,4-dibromo-2-phenyl-2H-furan-5-one
• CAS: 72857-86-4
• 化学式: C₁₀H₆Br₂O₂
• 分子量: 317.964
• InChiKey: NLXXYDCGRMDFBB-UHFFFAOYSA-N

物化性质

• 熔点：
  74-76°C
• 沸点：
  409.7±45.0 °C(Predicted)
• 密度：
  2.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932209090

反应信息

• 作为反应物：
  描述：

  3,4-二溴-5-苯基-2(5H)-呋喃酮 在 ammonium hydroxide 、 potassium carbonate 、 一水合肼 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 51.0h， 生成 5-methoxy-6-phenyl-3(2H)-pyridazinone
  参考文献：
  名称：

  哒嗪。第XXIX部分：5-取代的6-苯基-3（2H）-哒嗪酮的合成和血小板聚集抑制活性。他们的生物学行为的新颖方面。

  摘要：

  已经制备了一系列5-位具有5-取代基范围的6-苯基-3（2H）-哒嗪酮，并在寻找新的抗血小板药时对其进行了评估。已经观察到取代基对抑制作用的显着依赖性。这些化合物的药理研究证实，6-苯基-3（2H）-哒嗪酮系统第5位的化学基团的修饰既影响抗血小板活性的变化，又影响作用机理。

  DOI：

  10.1016/s0968-0896(02)00146-3
• 作为产物：
  描述：

  mucobromic acid 、 phenylmagnesium bromide 在 乙醚 作用下， 生成 3,4-二溴-5-苯基-2(5H)-呋喃酮
  参考文献：
  名称：

  Winogradowa; Schemjakin, Zhurnal Obshchei Khimii, 1946, vol. 16, p. 1279,1288

  摘要：

  DOI：

文献信息

• [EN] MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR DE PROSTACYCLINE (PGI2) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2010077275A1

  公开（公告）日：2010-07-08

  Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  环己烷衍生物的公式Ia和调节PGI2受体活性的药物组合物。本发明的化合物和药物组合物适用于治疗以下疾病：肺动脉高压（PAH）及相关疾病；血小板聚集；冠心病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤；在血管成形术或冠状动脉搭桥手术个体或房颤患者中形成血栓；动脉粥样硬化；动脉血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼内压异常的眼病；高血压；炎症；银屑病；银屑病关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺病（COPD）。
• Pyridazines.<b>XV</b>. Synthesis of 6-aryl-5-amino-3(2<i>H</i>)-pyridazinones as potential platelet aggregation inhibitors
  作者：Isabel Estevez、Enrique Raviña、Eddy Sotelo

  DOI：10.1002/jhet.5570350634

  日期：1998.11

  Several 3(2H)-pyridazinones with amino groups at the 5-position of the pyridazine nucleus have been prepared. The 6-aryl-5-halo-3(2H)-pyridazinones obtained from mucochloric and mucobromic acid lead to the corresponding 5-alkylamino-3(2H)-pyridazinones, which were tested as platelet aggregation inhibitors.

  已经制备了几个在哒嗪核的5-位具有氨基的3（2 H）-哒嗪酮。从粘氯酸和粘溴酸得到的6-芳基-5-卤代-3（2 H）-哒嗪酮导致相应的5-烷基氨基-3（2 H）-哒嗪酮，其被测试为血小板聚集抑制剂。
• MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Tran Thuy-Anh

  公开号：US20110245251A1

  公开（公告）日：2011-10-06

  Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  公式Ia的环己烷衍生物及其药物组成物，可调节PGI2受体的活性。本发明的化合物和药物组成物适用于治疗以下疾病的方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗塞；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤；血栓形成在血管成形术或冠状动脉旁路手术患者或患有房颤的个体中；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病性周围神经病、糖尿病性肾病或糖尿病性视网膜病变；青光眼或其他眼部异常内压疾病；高血压；炎症；牛皮癣；银屑病关节炎；类风湿性关节炎；克罗恩病；移植排斥反应；多发性硬化症；全身性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
  申请人：Tran Thuy-Anh

  公开号：US08940891B2

  公开（公告）日：2015-01-27

  Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  公式Ia的环己烷衍生物及其制药组合物，可调节PGI2受体的活性。本发明化合物及其制药组合物用于治疗以下疾病的方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗塞；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在血管成形术或冠状动脉旁路手术个体或患有心房颤动的个体；动脉粥样硬化；动脉粥样硬化性血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼部异常内压疾病；高血压；炎症；银屑病；银屑病关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Substituted pyridazines as prostacyclin receptor modulators
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10138210B2

  公开（公告）日：2018-11-27

  Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  可调节 PGI2 受体活性的式 Ia 环己烷衍生物及其药物组合物。本发明的化合物及其药物组合物适用于治疗以下疾病的方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗塞；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血管成形术或冠状动脉搭桥术患者或心房颤动患者的血栓形成；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼内压异常的眼部疾病；高血压；炎症；银屑病；银屑病关节炎；类风湿性关节炎；克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮 (SLE)、溃疡性结肠炎、缺血再灌注损伤、血管再狭窄、动脉粥样硬化、痤疮、1 型糖尿病、2 型糖尿病、败血症和慢性阻塞性肺病 (COPD)。